Driven by Science.

PGDx will continue advancing genomic diagnostics through regulated, kitted NGS systems, integrating optimized chemistry with automated bioinformatics.

Local testing. Global access.

Driven by Science.

PGDx will continue advancing genomic diagnostics through regulated, kitted NGS systems, integrating optimized chemistry with automated bioinformatics.

Local testing. Global access.

Inspired by Patients. Empowering Physicians.

PGDx is committed to delivering a comprehensive portfolio of kitted NGS solutions for oncology, from DNA to actionable information.

Local testing. Comprehensive genomic answers.

Inspired by Patients. Empowering Physicians.

PGDx is committed to delivering a comprehensive portfolio of kitted NGS solutions for oncology, from DNA to actionable information.

Local testing. Comprehensive genomic answers.

Committed to You.

Cancer patients today do not have all the answers they need to fight their disease effectively. We intend to change that.

Local testing. Comprehensive genomic answers.

Committed to You.

Cancer patients today do not have all the answers they need to fight their disease effectively. We intend to change that.

Local testing. Comprehensive genomic answers.

EMPOWERING THE FIGHT AGAINST CANCER

We are committed to improving clinical insight, speed of results, and health economics by delivering a portfolio of regulated tissue-based and liquid biopsy Next-Generation Sequencing (NGS) products to be used in laboratories worldwide.

 

 

Today, less than 20% of cancer patients receive genomic testing to inform their treatment path. 

 

 

We intend to change that.

 
 

Unlock Actionable Information
from the Genome

BIOMARKER DISCOVERY

Personal Genome Diagnostics (PGDx), founded by leading researchers from Johns Hopkins University, provides advanced cancer genome analysis to help researchers and partners identify elusive cancer-related genetic changes.

  • Sequence Mutations
  • Copy Number Alterations
  • Translocations

CDx CO-DEVELOPMENT

PGDx establishes co-development partnerships to create companion diagnostic products for personalized medicines of the future.

CLINICAL TRIALS

PGDx partners with pharmaceutical companies to help accelerate biomarker driven drug development.

GLOBAL PATIENT ACCESS TO IVD KITS

PGDx will offer tissue and liquid biopsy reagent kits with an automated bioinformatics pipeline, enabling local NGS testing in laboratories worldwide.

Personal Genome Diagnostics CE Marks Liquid Biopsy Test
Mar 14, 2019